BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv6.18.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20150329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20151025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20160327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20161030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20171029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160107
DTEND;VALUE=DATE:20160108
DTSTAMP:20151218T175506Z
CREATED:20151218T174519Z
LAST-MODIFIED:20151218T175506Z
UID:11932-1452124800-1452211199@ces.b2sg.org
SUMMARY:Research Grant Programm
DESCRIPTION:Supports research projects aimed at understanding the causes of breast cancer\, prevention or developing new treatments for metastatic breast cancer
URL:https://ces.b2sg.org/event/research-grant-programm/
CATEGORIES:Grants
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160107
DTEND;VALUE=DATE:20160109
DTSTAMP:20181103T130437Z
CREATED:20151218T172802Z
LAST-MODIFIED:20181103T130437Z
UID:11928-1452124800-1452297599@ces.b2sg.org
SUMMARY:USCAP 108th Annual Meeting: ASCP & ASIP Joint Meeting
DESCRIPTION:Current and Future Revolution in Pathology Practice: (Focus on) Immuno-oncology and Cancer Epigenetics \nASIP/ASCP will bring together 4 speakers from across two unique disciplines of pathology to discuss the practice\, science\, and challenges of immuno-oncology and cancer epigenetics intended to inform and education residents\, fellows\, and practicing pathologists.  The course will begin with a practical discussion of IO in current practice (Mamatha Chivukula\, Sutter Health\, CA) from the perspective of a community-based pathologist. This segment will review the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc.\, with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions. This will be followed up by a discussion of cutting-edge science in the IO space (Mike Milone\, UPenn) with emphasis on those technologies and tools that are likely to move into clinical space soon. This same approach to cancer epigenetics (David Williams\, UNC) will be revealed and discussed in the third presentation. Both of these cutting-edge talks will identify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics.  To finish off\, a “future talk” focused on how cancer epigenetics will affect patient care and everyday diagnostics will be presented (Idriss M. Bennani-Baiti\, President\, Cancer Epigenetics Society\, Vienna\, Austria). This portion will assess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care. \nCourse Learning Objectives\nUpon completion of this educational activity\, the learner will be able to: \n\nReview the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1)\, tumor mutational burden\, sequencing\, etc. with specific emphasis on treatment selection challenges\, quality across the testing/reporting spectrum\, pitfalls\, and practical solutions\nIdentify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics\nAssess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care\n\n\nSESSION CHAIRS\n\n\nModerator \nDanny Milner\, MD\, MSc\, ASCP\n\n\n\n\n\nPRESENTATIONS\n\n\n1:30 PM\n1:35 PM\n\n\nIntroduction to the Session and Outline of the Symposium Objectives\n\n\nDanny Milner\, MD\, MSc\nASCP\n\n\n\n\n\n\n\n1:35 PM\n2:10 PM\n\n\n“Immunotherapy” From Bench to Community Practice- Are Pathologists Ready for the #gamechanger?\n\n\nMamatha Chivukula\, MD\, FASCP\nMills-Peninsula Hospital\, Sutter Health Affiliate\n\n\n\n\n\n\n\n2:10 PM\n2:45 PM\n\n\nCutting Edge Science in Immuno-Oncology: Where to next?\n\n\nMichael Milone\, MD\, Phd\nUniversity of Pennsylvania Perelman School of Medicine\n\n\n\n\n\n\n\n2:45 PM\n3:20 PM\n\n\nBreak\n\n\n\n\n\n\n3:20 PM\n3:55 PM\n\n\nFrom DNA Methylation to Chromatin Remodeling\, the Expanding Role of Epigenetic Changes in Cancer Biology\n\n\nDavid Williams\, MD\, PhD\nUniversity of North Carolina at Chapel Hill\n\n\n\n\n\n\n\n3:55 PM\n4:30 PM\n\n\nPractical Epigenetics: How Today’s Cancer Epigenetics Research Will Change the Field of Pathology Tomorrow\n\n\nIdriss Bennani-Baiti\, PhD\nChildren’s Cancer Research Institute Vienna\n\n\n\n\n\n\n\n4:30 PM\n5:00 PM\n\n\nPanel Discussion\n\n\nDanny Milner\, MD\, MSc
URL:https://ces.b2sg.org/event/ascp-asip-joint-meeting/
LOCATION:National Harbor\, Maryland\, Singapore
CATEGORIES:Meetings
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160110
DTEND;VALUE=DATE:20160115
DTSTAMP:20160105T213716Z
CREATED:20151218T173720Z
LAST-MODIFIED:20160105T213716Z
UID:11934-1452384000-1452815999@ces.b2sg.org
SUMMARY:Metabolism\, Transcription and Disease
DESCRIPTION:Meeting Summary\n\nTo maintain homeostasis\, cells need to coordinate gene expression and metabolic state. There is increasing evidence that misregulation of metabolic flux and gene transcription plays a major role in human diseases\, including obesity\, diabetes and cancer. The aim of this meeting is to explore how metabolic state influences gene expression programs and\, conversely\, how intermediary metabolism is controlled by the transcription machinery and chromatin-modulating enzymes. Particular emphasis will be on the connection between gene transcription and metabolism in homeostatic and diseased state. Emerging evidence emphasizes that chromatin-modifying enzymes depend on substrates\, or co-factors\, that are key components of intermediary metabolism. The cellular concentration of these metabolites fluctuates in response to\, for example\, nutrient availability\, circadian cycles or oncogenic transformation. Thus\, chromatin might be considered a sensor of metabolic state. Moreover\, some metabolic enzymes play surprisingly direct roles in transcription control. Conversely\, transcriptional control of metabolic enzyme expression\, for example by nuclear receptors or the oncogene Myc\, plays a major role in maintaining homeostasis\, circadian rhythm or driving cell growth and proliferation. The aim of this Keystone Symposia meeting is to bring together scientists working on basic aspects of transcription control\, epigenetics\, metabolic disease and cancer. The meeting should serve as a discussion platform to explore the rapidly growing interphase between transcription regulation\, metabolic reprogramming and human disease.
URL:https://ces.b2sg.org/event/keystone-symposia-on-molecular-and-cellular-biology-metabolism-transcription-and-disease/
LOCATION:Unnamed Venue\, Snowbird\, UT\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2015/12/gyukjkjlklkl.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160119
DTEND;VALUE=DATE:20160120
DTSTAMP:20160111T205520Z
CREATED:20151218T181151Z
LAST-MODIFIED:20160111T205520Z
UID:11944-1453161600-1453247999@ces.b2sg.org
SUMMARY:Research Travel Award
DESCRIPTION:Cancer Research UK seeks to attract the best postdoctoral researchers to perform groundbreaking cancer research. The purpose of the Research Travel Awards is to enable ambitious postdoctoral researchers to visit research groups elsewhere in the UK or overseas to:\nIntroduce new expertise\, techniques or skills to the travelling scientist’s current research group  Establish or develop collaborations between research groups  Develop their own research career with a view to becoming an independent researcher  Attend a skills-based training course  Pursue a cancer-related project if they do not currently work in cancer research\nResearch Travel Awards are considered by the Research Travel Award Panel.
URL:https://ces.b2sg.org/event/research-travel-award/
CATEGORIES:Awards
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2015/12/Cancer-research-UK1.png
END:VEVENT
END:VCALENDAR